Dr Reddy's Laboratories inks agreement to acquire Nimbus Health GmbH

Dr Reddy's Laboratories on Thursday said it has inked a pact to acquire Germany-based Nimbus Health GmbH.

Dr Reddy's
Press Trust of India New Delhi
2 min read Last Updated : Feb 04 2022 | 12:24 AM IST

Dr Reddy's Laboratories on Thursday said it has inked a pact to acquire Germany-based Nimbus Health GmbH.

The drug major said it has entered into a definitive agreement to acquire the company which is a privately owned, licensed pharmaceutical wholesaler focusing on medical cannabis in Germany.

Dr Reddy's will acquire Nimbus Health for an upfront payment plus performance and milestone-based earn-outs over the next four years, the Hyderabad-based drug maker said in a regulatory filing.

The company however did not share financial details.

The acquisition will allow Dr Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients, it added.

"Medical cannabis is increasingly used to address and treat high unmet medical needs, especially in pain management and CNS. Further, with numerous studies being conducted to leverage and introduce medical cannabis, we believe this is a must-be field for future healthcare delivery," Dr Reddy's Head of European Generics Patrick Aghanian noted.

As more European countries adopt the usage of medical cannabis, the ability to leverage and access newer geographies will be key, he added.

Nimbus Health Founder and Managing Director Linus Maximilian Weber stated that the close alignment between the values of Dr Reddy's and Nimbus gave the company the confidence that the entities can stay focused on the existing business and grow future endeavours together.

Nimbus will operate as a wholly-owned subsidiary of Dr Reddy's, the drug maker stated.

The demand for medical cannabis has increased over the past years with the legalisation of medical cannabis by the German Parliament in 2017.

The medical cannabis market in Germany is already valued at 122 million euros with growth of 25 per cent in 2021 compared to 2020, making Germany one of the largest markets in Europe.

Around 1,50,000 German patients benefit from medical cannabis for their unmet health needs.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Dr Reddy's Lab

First Published: Feb 04 2022 | 12:24 AM IST

Next Story